Axsome therapeutics, inc. (AXSM)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities
Net loss

-90,188

-68,345

-53,135

-42,281

-36,800

-30,965

-28,798

-26,950

-25,753

-28,943

0

0

-29,330

-27,201

-23,237

-20,619

-15,936

-12,210

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

6,992

6,115

3,654

2,890

2,476

1,754

1,938

1,934

1,943

2,072

0

0

2,038

2,031

1,779

1,681

1,384

803

0

0

0

Non-cash research and development license expense

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt discount

720

649

553

465

374

375

411

442

463

470

0

0

0

-

-

-

-

42

0

0

0

Amortization of debt issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7

0

0

0

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

698

0

0

0

Change in fair value of warrants

-

-

-

-

-

-2,791

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant and embedded derivative liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

274

0

0

0

Depreciation

31

37

44

47

48

48

48

45

44

42

0

0

28

20

11

7

5

3

0

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-825

-833

-129

-373

13

-32

-22

345

-58

-102

0

0

191

383

522

911

926

870

0

0

0

Other assets

42

27

51

51

-13

-75

-1

-1

-4

75

0

0

61

86

0

0

0

-

-

-

-

Accounts payable

8,757

7,256

5,279

2,961

-440

251

1,224

-863

-866

-645

0

0

2,910

2,188

3,123

1,960

588

1,134

0

0

0

Accrued expenses and other current liabilities

5,599

7,105

5,025

1,824

1,586

1,163

644

676

-382

-140

0

0

451

2,080

2,347

1,730

1,893

700

0

0

0

Net cash used in operating activities

-60,149

-46,375

-38,601

-33,886

-32,872

-30,053

-26,550

-27,086

-26,515

-26,471

0

0

-23,970

-21,281

-16,315

-13,435

-10,227

-7,438

0

0

0

Cash flows from investing activities
Purchases of equipment

0

-

-

-

-

32

32

27

21

9

0

0

96

104

102

30

20

20

0

0

0

Net cash used in investing activities

0

-

-

-

-

-32

-32

-27

-21

-9

0

0

-96

-104

-102

-30

-20

-20

0

0

0

Cash flows from financing activities
Deferred financing fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Procceds from issuance of common stock upon financing, net

-

238,233

53,377

54,967

37,725

12,881

12,855

11,265

9,027

23,677

0

0

0

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock upon exercise of options

1,363

1,143

0

0

0

-

-

-

-

316

0

0

0

-

-

-

-

-

-

-

-

Proceeds from issuance of convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,382

0

0

0

Proceeds from issuance of term loan

-

20,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of principal on term loan

-

7,238

8,072

8,905

9,738

3,333

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds issuance of common stock upon exercise of warrants

-

-

-

-

-

-

-

-

-

167

0

0

0

-

-

-

-

-

-

-

-

Net cash (used in) provided by financing activities

214,863

252,388

67,037

67,308

48,882

10,034

10,131

9,471

8,150

23,884

0

0

0

-

-

-

-

52,877

0

0

0

Net (decrease) increase in cash

154,688

205,997

28,421

33,401

15,991

-20,052

-16,452

-17,643

-18,386

-2,597

0

0

941

-11,417

29,266

32,337

42,387

45,418

0

0

0

Supplemental disclosures of cash flow information:
Interest paid

1,450

1,287

1,166

965

781

771

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosures of non-cash financing activity:
Issuance of warrants in connection with debt financing

-

387

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrants issued for debt financing and offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0